Sverre E Kjeldsen Selected Research

Hypertension (High Blood Pressure)

06/2008	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
04/2008	Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
01/2008	Do screening blood pressure and plasma catecholamines predict development of hypertension? Twenty-year follow-up of middle-aged men.
11/2007	In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
09/2007	Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
05/2007	Arterial plasma vasopressin and aldosterone predict left ventricular mass in men who develop hypertension over 20 years.
02/2007	Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
01/2007	Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
01/2007	Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
12/2006	European Society of Hypertension Scientific Newsletter: update on hypertension management: prevention of type 2 diabetes mellitus with antihypertensive drugs.
08/2006	N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
05/2006	Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years.
03/2006	Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
01/2006	Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
11/2005	Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
09/2005	The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
06/2005	Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: LIFE, SCOPE, and VALUE.
04/2005	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
04/2005	Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
04/2005	Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
03/2005	The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
03/2005	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
03/2005	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
02/2005	Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
01/2005	Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide.
01/2005	Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
11/2004	Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
09/2004	Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
08/2003	Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
04/2003	An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
01/2003	[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]
01/2003	Serum uric acid and hemorheology in borderline hypertensives and in subjects with established hypertension and left ventricular hypertrophy.
09/2002	Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
09/2002	Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
03/2002	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
03/2002	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Articles by Research Topic

Disease

36	Hypertension (High Blood Pressure) 06/2008 - 03/2002
16	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 06/2008 - 09/2002
6	Stroke (Strokes) 01/2007 - 04/2003
4	Atrial Fibrillation 03/2008 - 03/2005
3	Diabetes Mellitus 11/2007 - 03/2006
2	Heart Failure 01/2007 - 01/2006
2	Myocardial Infarction 01/2007 - 01/2002
2	Type 2 Diabetes Mellitus (MODY) 12/2006 - 01/2006
2	Albuminuria 02/2005 - 09/2004
1	Bundle-Branch Block (Fascicular Block) 06/2008
1	Carotid Stenosis (Carotid Artery Stenosis) 03/2006
1	Cardiomegaly (Heart Hypertrophy) 01/2005
1	Vascular Diseases (Vascular Disease) 08/2003

Drug/Important Bio-Agent (IBA)

27	Losartan (Cozaar)FDA Link 06/2008 - 03/2002
17	Atenolol (Tenormin)FDA LinkGeneric 01/2007 - 01/2002
4	AngiotensinsIBA 11/2005 - 11/2004
3	Angiotensin Receptors (Angiotensin II Receptor)IBA 03/2008 - 03/2005
3	CholesterolIBA 01/2004 - 04/2003
2	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2007 - 01/2005
2	carvedilol (Coreg)FDA LinkGeneric 01/2007 - 01/2002
2	Antihypertensive Agents (Antihypertensives)IBA 12/2006 - 01/2006
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 05/2006 - 01/2002
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2005 - 11/2004
2	atorvastatin (Lipitor)FDA Link 01/2004 - 04/2003
1	CatecholaminesIBA 01/2008
1	Hemoglobins (Hemoglobin)IBA 09/2007
1	valsartan (Vals)FDA Link 09/2007
1	AldosteroneIBA 05/2007
1	Vasopressins (Vasopressin)IBA 05/2007
1	C-Reactive ProteinIBA 08/2006
1	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2006
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/2005
1	Insulin (Novolin)FDA Link 04/2005
1	Uric Acid (Urate)IBA 01/2003